FDA Unveils Inspections Database - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Unveils Inspections Database


ePT--the Electronic Newsletter of Pharmaceutical Technology

Last week, FDA added a searchable database of inspection data to its website. The database lists the names and addresses of facilities that the agency inspected during fiscal years 2009 and 2010. Users can find inspection dates, the type of FDA-regulated products that the facilities produced, and the agency’s final inspectional classification, which reflects each firm’s compliance status.

FDA made the database available as part of its Transparency Initiative, which is intended to increase public access to information about the agency’s enforcement and compliance-related activities. Disclosing companies’ compliance status is one way that the agency is explaining its enforcement actions to the public. FDA also intends this disclosure to inform public decisions, to provide information about company practices that may threaten public health, to highlight companies that have had satisfactory inspections, and to encourage compliance.

The database is hosted on FDA’s web portal for information about its enforcement activities. The portal also includes a summary of the most common Inspectional Observations of objectionable conditions or practices. By the end of 2011, FDA will begin to disclose information about FDA evaluations of filers, expand disclosure of Untitled Letters, and support industry efforts during food recalls.

In response to President Obama’s emphasis on openness in government, FDA Commissioner Margaret Hamburg launched FDA’s Transparency Initiative in June 2009. After holding public meetings and soliciting written comments, FDA drafted a report proposing 21 actions to increase disclosures about its activities. The database and web portal are among the first of these proposals to be implemented.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here